Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes ...

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to know ...

Isomorphic Labs, a Google-backed AI company, is set to begin human trials for cancer drugs designed by AI, raising both hope ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Alphabet-owned Isomorphic Labs says its first AI-designed drug is nearly ready for human trials, targeting diseases like cancer and heart failure. Nucleus_AI 2797 Stories Tuesday July 08, 2025 , 2 ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Google DeepMind's drug discovery arm, Isomorphic Labs, is almost ready to begin human trials of its AI-designed drugs.In an interview with Fortune, Colin Murdoch, President of Isomorphic Labs and ...

Google Cloud has unveiled two new suites of AI tools that aim to help the pharmaceutical industry accelerate drug discovery and make it cheaper. The suites, called Target and Lead Identification Suite ...

Google Ventures and Alphabet, an existing investor, also participated in the round. Top tech companies are racing to position AI-powered offerings as central to their products and services.

IntelliGen AI, an artificial intelligence (AI) start-up founded in Hong Kong, is positioning itself as a competitor to Google DeepMind in the field of drug discovery, as the city increasingly ...